Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/vasopressin-receptor-antagonists-SWibRMXcLW
References (81)
-
M. Thibonnier, P. Coles, D. Conarty, C. Plesnicher, M. Shoham (2000)
A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor.The Journal of pharmacology and experimental therapeutics, 294 1
-
K. Swedberg, P. Eneroth, J. Kjekshus (1990)
Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortalityCirculation, 82
-
S.A. Hunt, D.W. Baker, M.H. Chin (2001)
ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summaryJ Am Coll Cardiol, 38
-
D. Hayoz, G. Bizzini, B. Noel (2000)
Effect of SR 49059, a V1a vasopressin antagonist, in Raynaud’s phenomenonRheumatology, 39
-
J. Albright, M. Reich, E. Santos, J. Dusza, F. Sum, A. Venkatesan, J. Coupet, P. Chan, X. Ru, H. Mazandarani, T. Bailey (1998)
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.Journal of medicinal chemistry, 41 14
-
A. Ohnishi, Y. Orita, N. Takagi, T. Fujita, T. Toyoki, Y. Ihara, Y. Yamamura, T. Inoue, T. Tanaka (1995)
Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.The Journal of pharmacology and experimental therapeutics, 272 2
-
M. Packer, M.R. Bristow, J.N. Cohn (1996)
The effect of Carvedilol on morbidity and mortality in patients with chronic heart failureN Engl J Med, 334
-
B. Mayinger, J. Hensen (2009)
Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 107 3
-
M. Weinfeld, G. Chertow, L. Stevenson (1999)
Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure.American heart journal, 138 2 Pt 1
-
W.T. Abraham, R.M. Oren, T.S. Crisman (1997)
Effects of an oral, nonpeptide, selective V2 receptor vasopressin antagonist in patients with chronic heart failure [abstract]J Am Coll Cardiol, 29
-
G.S. Francis, C. Benedict, D.E. Johnstone (1990)
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failureCirculation, 82
-
CIBIS-II Committees (1999)
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 353
-
W.B. Smith, S. Russell, J.K. Ghali (2001)
Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure [abstract]Eur Heart J, 22
-
R. Brouard, V. Laporte, C. Gal, R. Pignol, H. Jang, F. Donat, G. Lockwood, D. Fournie, F. Dreux (1998)
Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.Advances in experimental medicine and biology, 449
-
B. Walker, M. Childs, E. Adams (1988)
Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors.The American journal of physiology, 255 2 Pt 2
-
Å. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, G. Westergren, M. Thimell, D. Allaf, J. Vítovec, J. Aldershvile, M. Halinen, R. Dietz, K. Neuhaus, A. Jánosi, G. Thorgeirsson, P. Dunselman, L. Gullestad, J. Kuch, J. Herlitz, P. Rickenbacher, S. Ball, S. Gottlieb, P. Deedwania, G. Vandenhoven, I. Novakova, S. Danker, M. Lundström, W. Meyer-Sabellek, I. Balla, M. Sveinsdóttir, B. Dorhout, A. Hildebrandt, I. Szczurko, C. Larsson, E. Bucher, E. Scott, D. Dwyer, D. Julian, D. DeMets, K. Chatterjee, J. Feyzi, S. Lehto, P. Karpati, W. Motz, O. Samuelsson, J. Viersma, B. Andersson, C. Berthe, J. Boutefeu, G. Boxho, P. Decroly, J. Derbaudrenghien, J. Pirlet, P. Henry, G. Heyndrickx, L. Missault, M. Nannan, P. Timmermans, J. Vachiéry, W. Mieghem, J. Vandenbossche, K. Dvořák, M. Herold, J. Hradec, A. Kana, P. Petr, J. Rybka, J. Šmid, P. Svítil, J. Toman, E. Agner, O. Amtorp, K. Egstrup, P. Eliasen, C. Gøtzsche, P. Hildebrandt, A. Johannesen, P. Kaiser-Nielsen, H. Nielsen, P. Nielsen, F. Pedersen, J. Nielsen, K. Skagen, T. Honkanen, E. Hussi, J. Juvonen, H. Jääskeläinen, J. Rinne, T. Salonen, D. Andresen, H. Berwing, Bethge, Beythien, Bischoff, Bundschu, Daniel, Darius, Delius, Drude, Dingerkus, Dück, Eichler, Fach, A. Förster, Girth, Goss, Hahn, Hambrecht, G. Hauf, Heinemann, Hepp, Janka, Klocke, Konz, B. Krosse, Kühlkamp, Lewek, B. Lüderitz, Löbe, Maier, Melchior, Müller, Mäurer, Nast, Neuhaus, Obst, Odemar, K. Olshausen, Pomykaj, K. Schmailzl, Schrader, Schröder, P. Schwimmbeck, M. Sigmund, Simon, Strasser, Thilo, Vöhringer, H. Völler, Weibrodt, Wirtz, I. Czuriga, M. Hetey, A. Katona, M. Lengyel, A. Nyárádi, A. Rednik, K. Sándori, P. Szabó, J. Tarján, J. Tenczer, S. Timar, P. Vályi, G. Veress, K. Zámolyi, B. Öze, G. Thorgeirsson, G. Thorgeirsson, P. Bernink, A. Bredero, R. Breedveld, P. Breuls, J. Bucx, J. Cornel, P. Milliano, P. Dunselman, B. Hamer, N. Holwerda, J. Hoogsteen, J. Hoorntje, J. Kragten, A. Liem, G. Linssen, H. Michels, A. Misier, H. Schaafsma, P. Sijbring, R. Taverne, L. Kempen, R. Stralen, P. Veldhuisen, M. Veerhoek, C. Werter, J. Wesdorp, A. Willems, A. Withagen, P. Zwart, R. Bjørnerheim, M. Dahle, K. Dickstein, G. Frøland, T. Gundersen, K. Hofsoy, T. Hole, T. Johansen, J. Mannsverk, P. Nesje, T. Omland, C. Sjödin, P. Smith, H. Tjonndal, O. Vikesdal, K. Waagé, Adamus, K. Jaworska, P. Kołodziej, Z. Kornacewicz‐Jach, M. Krzeminska-Pakula, J. Piotrowski, W. Piwowarska, A. Stogowski, J. Wodniecki, K. Wrabec, P. Ahlström, S. Ekdahl, L. Hemmingson, L. Holmberg, B. Lernfelt, H. Widgren, K. Ångman, P. Erne, P. Mohacsi, R. Polikar, H. Schläpfer, P. Batin, K. Berkin, T. Callaghan, J. Forfar, M. Frenneaux, R. Greenbaum, M. Maltz, D. Murdoch, G. Reynolds, J. Stephens, A. Struthers, J. Swan, G. Tildesley, A. Abbasi, P. Alagona, J. Alderman, M. Alipour, Jeffrey Anderson, Z. Ansari, M. Ashraf, B. Beanblossom, S. Bennett, D. Benvenuti, M. Berk, R. Bhalla, S. Bilazarian, K. Browne, C. MBuchter, R. Carlson, C. Carlson, K. Danisa, I. Dauber, M. Dewood, G. Dennish, D. Denny, R. Dibianco, P. Diller, M. Dunlap, K. Dowd, A. Edmiston, M. Shahawy, U. Elkayam, J. Farnham, P. Fenster, S. Friedman, T. Heywood, J. Galichia, M. Geller, J. Ghali, M. Gheorghiade, T. Giles, R. Gillespe, G. Goldberg, M. Goldberg, D. Goldscher, G. Gooden, M. Goodman, L. Goodman, J. Gorwit, S. Gottlieb, A. Gradman, D. Grech, T. Hack, J. Hall, M. Hattenhauer, M. Higginbotham, S. Hutchins, M. Imburgia, B. Iteld, B. Jackson, S. Jafri, W. Jauch, S. Jennison, B. Kahn, W. Kao, K. Kaplan, R. Karlsberg, H. Kennedy, J. Kennedy, L. Kirkegaard, D. Kraus, K. Labresh, L. Lalonde, M. Lesser, R. Levites, M. Lévy, R. Lewis, I. Loh, H. Madyoon, F. Maislos, D. Mann, G. Maurice, A. Nisar, W. Old, J. Pappas, K. Phadke, S. Promisloff, A. Rashkow, B. Reeves, J. Rosen, M. Rotman, T. Saleem, S. Savran, R. Shah, Y. Shalev, J. Shanes, M. O'Shaughnessy, B. Silverman, R. Steingart, L. Swenson, K. Syed, U. Thadani, R. Thorsen, M. Tonkon, R. Touchon, G. Uhl, K. Vaska, S. Wagner, C. Weaver, R. Weiss, W. Wickemeyer, H. Willens, J. Wilson, R. Wright, L. Yellen (1999)
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 353
-
W. Colucci, U. Elkayam, D. Horton, W. Abraham, R. Bourge, Allen Johnson, L. Wagoner, M. Givertz, C. Liang, M. Neibaur, W. Haught, T. LeJemtel (2000)
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.The New England journal of medicine, 343 4
-
C. Pandozi, M. Santini (2001)
Update on atrial remodelling owing to rate; does atrial fibrillation always 'beget' atrial fibrillation?European heart journal, 22 7
-
Y. Yamamura, Shigeki Nakamura, S. Itoh, T. Hirano, T. Onogawa, Tatsuya Yamashita, Yoshihisa Yamada, K. Tsujimae, M. Aoyama, K. Kotosai, H. Ogawa, Hiroshi Yamashita, K. Kondo, M. Tominaga, G. Tsujimoto, Toyoki Mori (1998)
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.The Journal of pharmacology and experimental therapeutics, 287 3
-
G. Francis, C. Benedict, D. Johnstone, P. Kirlin, J. Nicklas, C. Liang, S. Kubo, Elizabeth Rudin-Toretsky, S. Yusuf (1990)
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).Circulation, 82 5
-
A. Ohnishi, Y. Ko, Hiroaki Fujihara, G. Miyamoto, K. Okada, M. Odomi (1993)
Pharmacokinetics, Safety, and Pharmacologic Effects of OPC‐21268, a Nonpeptide Orally Active Vasopressin V1 Receptor Antagonist, in HumansThe Journal of Clinical Pharmacology, 33
-
M. Manning, W. Sawyer (1982)
Antagonists of vasopressor and antidiuretic responses to arginine vasopressin.Annals of internal medicine, 96 4
-
M. Tonkon, G. Aronoff, G. Weisfogel (2001)
Interaction between furosemide and oral conivaptan (YM087) in patients with heart failure [abstract]Eur Heart J, 22
-
K. Swedberg, P. Eneroth, J. Kjekshus, L. Wilhelmsen (1990)
Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.Circulation, 82 5
-
S. Nielsen, C. Chou, D. Marples, E. Christensen, B. Kishore, M. Knepper (1995)
Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane.Proceedings of the National Academy of Sciences of the United States of America, 92 4
-
M. Burnier, A.F. Fricker, D. Hayoz (1999)
Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjectsEur J Clin Pharmacol, 55
-
G.L. Robertson (2001)
Harrison’s principles of internal medicine -
A. Tahara, Y. Tomura, K. Wada, T. Kusayama, J. Tsukada, M. Takanashi, T. Yatsu, W. Uchida, A. Tanaka (1997)
Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.The Journal of pharmacology and experimental therapeutics, 282 1
-
Solvd Investigators, S. Yusuf, B. Pitt, C. Davis, W. Hood, J. Cohn (1992)
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.The New England journal of medicine, 327 10
-
M. Thibonnier, A. Hinko, A. Pearlmutter (1987)
The Human Platelet Vasopressin Receptor and Its Intracellular Messengers: Key Role of Divalent CationsJournal of Cardiovascular Pharmacology, 10
-
C. Gal (1998)
Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.Advances in Experimental Medicine and Biology, 449
-
L. Wong, J. Verbalis (2001)
Vasopressin V2 receptor antagonists.Cardiovascular research, 51 3
-
M. Packer, M. Bristow, J. Cohn, W. Colucci, M. Fowler, E. Gilbert, N. Shusterman (1996)
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.The New England journal of medicine, 334 21
-
Y. Yamamura, H. Ogawa, H. Yamashita, T. Chihara, H. Miyamoto, Shigeki Nakamura, T. Onogawa, Tatsuya Yamashita, T. Hosokawa, Toyoki Mori, M. Tominaga, Y. Yabuuchi (1992)
Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonistBritish Journal of Pharmacology, 105
-
J. Cohn, G. Tognoni (2001)
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.The New England journal of medicine, 345 23
-
P. Nicod, B. Waeber, J. Bussien, J. Goy, G. Turini, J. Nussberger, K. Hofbauer, H. Brunner (1985)
Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure.The American journal of cardiology, 55 8
-
D. Hayoz, G. Bizzini, B. Noël, M. Depairon, M. Burnier, C. Fauveau, A. Rouillon, R. Brouard, H. Brunner (2000)
Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.Rheumatology, 39 10
-
A. Naito, Y. Ohtake, H. Hasegaw, A. Fukaya, T. Kurasawa, K. Naito, H. Matsukawa, T. Oguma, Y. Ezure, Y. Tsuriya, H. Tanaka, K. Koike, K. Shigenobu (2000)
Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.Biological & pharmaceutical bulletin, 23 2
-
J. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, Raphaelf Smith, W. Dunkman, H. Loeb, M. Wong, G. Bhat, S. Goldman, R. Fletcher, J. Doherty, C. Hughes, P. Carson, G. Cintron, R. Shabetai, C. Haakenson (1991)
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.The New England journal of medicine, 325 5
-
(1999)
PHARMACOKINETICS AND DISPOSITION -
J. Udelson, W. Smith, G. Hendrix, C. Painchaud, M. Ghazzi, I. Thomas, J. Ghali, P. Selaru, F. Chanoine, M. Pressler, M. Konstam (2001)
Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart FailureCirculation: Journal of the American Heart Association, 104
-
R. Turner, John Pierce, V. Vigneaud (1951)
The purification and the amino acid content of vasopressin preparations.The Journal of biological chemistry, 191 1
-
P. Chan, J. Coupet, H. Park, F. Lai, D Hartupee, P. Cervoni, J. Dusza, J. Albright, X. Ru, H. Mazandarani, T. Tanikella, C. Shepherd, L Ochalski, T. Bailey, T. Lock, X. Ning, J. Taylor, W. Spinelli (1998)
VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.Advances in experimental medicine and biology, 449
-
M. Packer, W. Lee, P. Kessler, S. Gottlieb, J. Bernstein, M. Kukin (1987)
Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.Circulation, 75 5 Pt 2
-
J. Tsukada, A. Tahara, Y. Tomura, K. Wada, T. Kusayama, N. Ishii, T. Yatsu, W. Uchida, N. Taniguchi, A. Tanaka (2001)
Effects of YM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cellsBritish Journal of Pharmacology, 133
-
K. Kondo, H. Ogawa, H. Yamashita, H. Miyamoto, Michinori Tanaka, Kenji Nakaya, K. Kitano, Y. Yamamura, Shigeki Nakamura, T. Onogawa, Toyoki Mori, M. Tominaga (1999)
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.Bioorganic & medicinal chemistry, 7 8
-
G. Francis, J. Cohn, G. Johnson, T. Rector, S. Goldman, Ada Simon (1993)
Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT IICirculation, 87
-
K. Adams, K. Baughman, M. Konstam, W. Dec, Peter Liu, U. Elkayam, B. Massie, A. Forker, J. Patterson, M. Gheorghiade, M. Silver, Denise Hermann, L. Stevenson (1999)
Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches.Journal of cardiac failure, 5 4
-
K. Skorecki, A. Verkman, C. Jung, D. Ausiello (1986)
Evidence for vasopressin activation of adenylate cyclase by subunit dissociation.The American journal of physiology, 250 1 Pt 1
-
C. Gal (1998)
Nonpeptide Antagonists for Vasopressin Receptors -
V. Szatalowicz, P. Arnold, C. Chaimovitz, D. Bichet, T. Berl, R. Schrier (1981)
Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure.The New England journal of medicine, 305 5
-
M. Thibonnier, D. Conarty, Judith Preston, P. Wilkins, L. Berti-Mattera, R. Mattera (1998)
Molecular pharmacology of human vasopressin receptors.Advances in experimental medicine and biology, 449
-
B. Pitt, F. Zannad, W. Remme, R. Cody, A. Castaigne, Alfonso Perez, J. Palensky, J. Wittes (1999)
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.The New England journal of medicine, 341 10
-
L. Burrell, J. Risvanis, C. Johnston, M. Naitoh, L. Balding (2000)
Vasopressin receptor antagonism — a therapeutic option in heart failure and hypertensionExperimental Physiology, 85
-
D. Huang, I. Pfaff, C. Gal, V. Vallon (2000)
Acute renal response to the non-peptide vasopressin V2-receptor antagonist SR 121463B in anesthetized ratsNaunyn-Schmiedeberg's Archives of Pharmacology, 362
-
Marc Thibonnier, Ahmad Kilani, Mahboob Rahman, Tina DiBlasi, Kelly Warner, M. Smith, Anne Leenhardt, Rémi Brouard (1999)
Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.Hypertension, 34 6
-
L. Burrell, P. Phillips, K. Rolls, B. Buxton, C. Johnston, J. Liu (1994)
Vascular responses to vasopressin antagonists in man and rat.Clinical science, 87 4
-
R. Michell, Christopher Kirk, M. Billah (1979)
Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin.Biochemical Society transactions, 7 5
-
S. Nielsen, S. Nielsen, S. Nielsen, D. Marples, D. Marples, D. Marples, Jørgen Frøklær, Jørgen Frøklær, Jørgen Frøklær, M. Knepper, M. Knepper, M. Knepper, P. Agre, P. Agre, P. Agre (1996)
The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2.Kidney international, 49 6
-
J. Walker, I. Wendt, Colin Gibbs (1988)
Heat production of rat anococcygeus muscle during isometric contraction.The American journal of physiology, 255 4 Pt 1
-
R. Schrier, T. Berl, R. Anderson (1979)
Osmotic and nonosmotic control of vasopressin release.The American journal of physiology, 236 4
-
J. Nemanich, R. Veith, I. Abrass, J. Stratton (1990)
Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy.The American journal of cardiology, 66 10
-
D. Bichet (1996)
Vasopressin receptors in health and disease.Kidney international, 49 6
-
Rémi Brouard, T. Bossmar, D. Fournié-Lloret, D. Chassard, Mats Åkerlund (2000)
Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoeaBJOG: An International Journal of Obstetrics & Gynaecology, 107
-
L. Share (1988)
Role of vasopressin in cardiovascular regulation.Physiological reviews, 68 4
-
James, Terris, Carolyn, A. Ecelbarger, Wren, Nielsen, Mark, A. Knepper (1996)
Long-term regulation of four renal aquaporins in rats.The American journal of physiology, 271 2 Pt 2
-
C. Gal, J. Wagnon, C. García, C. Lacour, P. Guiraudou, B. Christophe, G. Villanova, D. Nisato, J. Maffrand, G. Fur (1993)
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.The Journal of clinical investigation, 92 1
-
S. Yusuf, B. Pitt, C. Davis, W. Hood, J. Cohn (1991)
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.The New England journal of medicine, 325 5
-
M. Packer, A. Coats, M. Fowler, H. Katus, H. Krum, P. Mohacsi, J. Rouleau, M. Tendera, A. Castaigne, E. Roecker, M. Schultz, D. DeMets (2001)
Effect of carvedilol on survival in severe chronic heart failure.The New England journal of medicine, 344 22
-
A. Ohnishi, Y. Orita, R. Okahara, H. Fujihara, T. Inoue, Y. Yamamura, Y. Yabuuchi, T. Tanaka (1993)
Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.The Journal of clinical investigation, 92 6
-
K.T. Weber (1995)
Heart failure: its progressive natureAdv in Cardiovasc Med, 2
-
S. Goldsmith (1999)
Vasopressin: a therapeutic target in congestive heart failure?Journal of cardiac failure, 5 4
-
J. Sands, H. Nonoguchi, M. Knepper (1987)
Vasopressin effects on urea and H2O transport in inner medullary collecting duct subsegments.The American journal of physiology, 253 5 Pt 2
-
A. Hunt, David Baker, Marshall Chin, Michael Cinquegrani, A. Feldman, Gary Francis, Theodore Ganiats, Sidney Goldstein, G. Gregoratos, L. Jessup, R. Noble, Milton Packer, Marc Silver, L. Stevenson, R. Gibbons, Elliott Antman, Valentin Fuster, A. Jacobs, L. Hiratzka, Richard Russell, Sidney Smith (2002)
ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary -
K.F. Adams, K.L. Baughman, W.G. Dec (1999)
HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approachesJ Card Fail, 5
-
S. Jard (1988)
Mechanisms of action of vasopressin and vasopressin antagonists.Kidney international. Supplement, 26
-
Paul Kalra, S. Anker, S. Anker, Andrew Coats (2001)
Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin.Cardiovascular research, 51 3
-
W.S. Colucci, U. Elkayam, D.P. Horton (2000)
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failureN Engl J Med, 343
-
C. Gal, C. Lacour, G. Valette, G. Garcia, Loic Foulon, G. Galindo, L. Bankir, B. Pouzet, G. Guillon, C. Barberis, Danielle Chicot, S. Jard, P. Vilain, Corine Garcia, E. Marty, Danielle Raufaste, Gabrielle Brossard, D. Nisato, J. Maffrand, G. Fur (1996)
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.The Journal of clinical investigation, 98 12
-
Steven Goldsmith, Gary Francis, Allen Cowley, T. Levine, Jay Cohn (1983)
Increased plasma arginine vasopressin levels in patients with congestive heart failure.Journal of the American College of Cardiology, 1 6
-
H. Cooper, D. Dries, C. Davis, Y. Shen, M. Domanski (1999)
Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.Circulation, 100 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2003 by Adis International Limited
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.2165/00129784-200303010-00002
- pmid
- 14727942
- Publisher site
- See Article on Publisher Site
Abstract
Despite the use of ACE inhibitors and β-blockers, the morbidity and mortality of patients with chronic heart failure remains quite high. This has stimulated the development of new therapies, many based on the neurohormonal hypothesis. There are now multiple agents being developed for the treatment of heart failure designed to block many of the neurohormones that are increased in these patients. One of the hormones that is increased in chronic heart failure is vasopressin. Vasopressin reduces free water secretion and at high concentrations, causes vasoconstriction in the peripheral vasculature. Antagonists to vasopressin will promote free water excretion (aquaresis) and vasodilatation with a subsequent reduction in afterload. In theory, these agents would be beneficial for both acute exacerbations of heart failure (free water excretion) and chronic heart failure (neurohormonal blockade). We review the potential uses of these antagonists for these two conditions and the promising results of small, hemodynamic trials with the new vasopressin antagonists that have already been performed.
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012